Eckert & Ziegler Strahlen- und Medizintechnik AG (DE:EUZ)
XETRA:EUZ
Top Page
Eckert & Ziegler Strahlen und Medizintechnik
(XETRA:EUZ)
Select Model
Select Model
Rating:67Neutral
Price Target:
€16.00
▲(11.34% Upside)
Action:ReiteratedDate:03/29/26
The score is driven primarily by solid financial performance (strong profitability and a conservative balance sheet), partially offset by inconsistent free cash flow. Technical signals are weak with the stock trading below key moving averages and negative MACD, and valuation is somewhat stretched given the ~33 P/E with only a modest dividend yield.
Positive Factors
Conservative balance sheet
Low leverage and rising equity provide durable financial flexibility: the company can fund regulatory compliance, capacity investment or small M&A without large refinancing needs. A conservative balance sheet reduces solvency risk and interest expense sensitivity across cycles.
Negative Factors
Volatile free cash flow
Wide swings in free cash flow reduce predictability of internal funding and complicate capital allocation. Volatility may force ad hoc financing or constrain dividends and reinvestment during weaker years, increasing execution risk for long-term projects.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and rising equity provide durable financial flexibility: the company can fund regulatory compliance, capacity investment or small M&A without large refinancing needs. A conservative balance sheet reduces solvency risk and interest expense sensitivity across cycles.
Read all positive factors
Eckert & Ziegler Strahlen und Medizintechnik (EUZ) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€914.83M
Dividend Yield1.11%
Average Volume (3M)108.96K
Price to Earnings (P/E)19.6
Beta (1Y)1.22
Revenue Growth9.64%
EPS Growth35.18%
CountryDE
Employees1,085
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.30
Shares Outstanding63,515,797
10 Day Avg. Volume81,969
30 Day Avg. Volume108,959
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)3.79
Price to Sales (P/S)3.06
P/FCF Ratio27.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.15Price Target Upside54.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.83
Revenue Forecast (FY)€338.93M
Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model
Company Description
Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Produ...
How the Company Makes Money
EUZ makes money primarily by selling radiation- and radioisotope-based products and related services into medical and life-science markets. Key revenue streams include: (1) Sales of radioisotopes and radiopharmaceutical inputs used by customers to...
Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
65
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 311.96M | 295.85M | 246.09M | 222.26M | 180.44M |
| Gross Profit | 147.21M | 143.16M | 116.34M | 106.78M | 91.08M |
| EBITDA | 92.13M | 77.38M | 59.67M | 57.90M | 56.68M |
| Net Income | 48.76M | 33.28M | 26.30M | 29.28M | 34.53M |
Balance Sheet | |||||
| Total Assets | 485.68M | 442.40M | 439.36M | 416.84M | 347.73M |
| Cash, Cash Equivalents and Short-Term Investments | 128.76M | 118.36M | 68.00M | 82.70M | 95.02M |
| Total Debt | 44.80M | 55.34M | 56.30M | 49.59M | 26.97M |
| Total Liabilities | 232.25M | 217.18M | 215.27M | 203.21M | 155.20M |
| Stockholders Equity | 251.77M | 223.45M | 222.18M | 212.07M | 187.39M |
Cash Flow | |||||
| Free Cash Flow | 34.39M | 49.38M | 21.12M | 3.17M | 5.00M |
| Operating Cash Flow | 60.41M | 66.57M | 46.95M | 34.30M | 33.85M |
| Investing Cash Flow | -25.93M | -16.59M | -42.74M | -41.04M | -23.59M |
| Financing Cash Flow | -21.53M | -9.99M | -9.28M | -5.71M | -6.06M |
Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis
Negative
14.37
Price Trends
14.83
Negative
15.20
Negative
16.97
Negative
Market Momentum
-0.10
Negative
46.55
Neutral
42.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Negative. The current price of 14.37 is below the 20-day moving average (MA) of 14.55, below the 50-day MA of 14.83, and below the 200-day MA of 16.97, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 46.55 is Neutral, neither overbought nor oversold. The STOCH value of 42.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:EUZ.
Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €41.86M | 14.26 | 13.44% | 3.86% | -5.72% | -25.19% | |
67 Neutral | €914.83M | 19.58 | 20.78% | 1.11% | 9.64% | 35.18% | |
57 Neutral | €42.14B | 27.87 | 11.65% | 2.13% | 4.53% | 10.12% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | €589.60M | -30.69 | 1.59% | 0.15% | 11.83% | -79.57% | |
49 Neutral | €215.89M | 58.01 | 6.55% | 2.71% | -1.64% | 22.60% |
* General Sector Average
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
14.62
-2.17
-12.90%
DE:GXI
Gerresheimer
17.07
-35.89
-67.77%
DE:M3V
MeVis Medical Solutions
23.00
-1.86
-7.50%
DE:SBS
STRATEC Biomedical
17.76
-4.82
-21.35%
DE:SHL
Siemens Healthineers AG
37.77
-5.49
-12.69%
DE:MF6
MagForce AG
0.01
>-0.01
-33.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.